drugset

drugset / Trial / NCT06661733

A Study to Investigate the Pharmacokinetics, Safety and Tolerability of AZD5462 in Participants With Renal Impairment

NCT06661733 ↗

Phase 1 Completed 16 enrolled AstraZeneca

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the pharmacokinetics (PK), safety, and tolerability of AZD5462 in participants with impaired renal function.

Timeline

Start: 2024-11-18
Primary completion: 2024-12-23
Completion: 2024-12-23

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AZD5462	Unknown	—	Oral

Indications